These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38965835)

  • 1. Molecular dynamics simulation and purification of chimeric L1/L2 protein from
    Al Adawiah R; Zaenal Mustopa A; Budiarti S; Nur Umami R; Hertati A; Irawan H; Ikramullah MC; Arwansyah A; Mamangkey J; Kartikasari I; Salahudin Darusman H
    J Immunoassay Immunochem; 2024 Jul; ():1-20. PubMed ID: 38965835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
    Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
    Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
    Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
    J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction, expression, and in vitro assembly of virus-like particles of L1 protein of human papillomavirus type 52 in Escherichia coli BL21 DE3.
    Mustopa AZ; Meilina L; Irawan S; Ekawati N; Fathurahman AT; Triratna L; Kusumawati A; Prastyowati A; Nurfatwa M; Hertati A; Harmoko R
    J Genet Eng Biotechnol; 2022 Feb; 20(1):19. PubMed ID: 35132511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
    Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
    J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles.
    Xu YF; Wang QY; Zhang HT; Han YH; Song GX; Xu XM
    Chin Med J (Engl); 2007 Mar; 120(6):503-8. PubMed ID: 17439745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.
    Wang D; Li Z; Xiao J; Wang J; Zhang L; Liu Y; Fan F; Xin L; Wei M; Kong Z; Yu H; Gu Y; Zhang J; Li S; Xia N
    PLoS One; 2015; 10(4):e0123944. PubMed ID: 25905781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
    PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and Immunogenicity.
    Chabeda A; van Zyl AR; Rybicki EP; Hitzeroth II
    Front Plant Sci; 2019; 10():779. PubMed ID: 31281327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of human papillomavirus chimaeric L1/L2 candidate vaccines.
    McGrath M; de Villiers GK; Shephard E; Hitzeroth II; Rybicki EP
    Arch Virol; 2013 Oct; 158(10):2079-88. PubMed ID: 23636405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
    Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
    Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
    Paz De la Rosa G; Monroy-García A; Mora-García Mde L; Peña CG; Hernández-Montes J; Weiss-Steider B; Gómez-Lim MA
    Virol J; 2009 Jan; 6():2. PubMed ID: 19126233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
    Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB
    PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles.
    Xu Y; Zhang H; Xu X
    FEMS Immunol Med Microbiol; 2008 Jan; 52(1):99-109. PubMed ID: 17995958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.
    Kalnin K; Tibbitts T; Yan Y; Stegalkina S; Shen L; Costa V; Sabharwal R; Anderson SF; Day PM; Christensen N; Schiller JT; Jagu S; Roden RB; Almond J; Kleanthous H
    Vaccine; 2014 Jun; 32(28):3540-7. PubMed ID: 24780250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized production strategy of the major capsid protein HPV 16L1 non-assembly variant in E. coli.
    Roos N; Breiner B; Preuss L; Lilie H; Hipp K; Herrmann H; Horn T; Biener R; Iftner T; Simon C
    Protein Expr Purif; 2020 Nov; 175():105690. PubMed ID: 32681956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The soluble expression and application of human papillomavirus type 58 (HPV58) major capsid protein L1].
    Chen Y; Li N; Xue M; Zhou J; Qi Y; Yin J; Zhang Y; Li Y; Wang A
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Jun; 38(6):553-558. PubMed ID: 35732612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice.
    Chen CW; Saubi N; Joseph-Munné J
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.